양극성 장애 시장 평가 : 유형별, 약물 종류별, 장애 유형별, 투여 경로별, 유통 채널별, 지역별 기회 및 예측(2017-2031년)

Global bipolar disorder market is projected to witness a CAGR of 3.01% during the forecast period 2024-2031, growing from USD 5.01 billion in 2023 to USD 6.35 billion in 2031. The growth in the bipolar disorder market is anticipated to be fueled by factors like the growing disease burden of bipolar disorder worldwide, growing concerns about mental health, increased diagnostics methods for early and effective diagnosis coupled with innovative product offerings from market players.

Bipolar disorder is a mental health condition characterized by extreme mood swings, including episodes of mania and depression. Treatment typically involves a combination of medications, such as mood stabilizers and antipsychotics, and psychotherapy, including cognitive behavioral therapy (CBT). A personalized approach is essential, often incorporating lifestyle changes and support systems to help manage symptoms effectively. Regular monitoring and adjustments to the treatment plan are crucial for achieving stability and improving the quality of life for individuals with bipolar disorders. The market for pharmaceutical treatment options for bipolar disorder is on the rise owing to increased emphasis on mental health and attention being given to mental wellness these days. The stigma associated with mental diseases is now clearing up, thus opening the door to opportunities for better treatment. Early diagnostic methods that utilize digital tools like wearable devices and artificial intelligence further drive the growth in the market. The major challenge in this market is the longer duration of treatment and patient adherence to it. However, the efforts of market players to provide better alternatives keep market growth on the rise. For instance, in April 2024, Vanda Pharmaceuticals Inc. received FDA approval for its atypical antipsychotic Fanapt (iloperidone) to treat manic or mixed episodes in adults with bipolar I disorder. Based on a Phase III clinical trial involving around 400 patients, this approval demonstrated significant improvements in mania severity compared to placebo. Fanapt, previously approved for schizophrenia, offers flexible dosing and a well-established safety profile.

Growing Bipolar Disease Burden to Boost Market Demand

The rising tide of bipolar disorder has a profound implication on the demand side of this market for therapeutics. Growing awareness and more developed diagnostic practices have increased the prevalence, so more patients find treatment. Extreme mood swings characterize bipolar disorder; hence the condition continues to create continuous demand for mood stabilizers, antipsychotics, and psychotherapy. Increased loss of productivity and healthcare costs attributable to the disorder have made governments and organizations concentrate more on initiatives that improve mental health, thus pushing the growth rate even higher in the market. Advances in research and development have also resulted in novel therapies that are effective and attractive to treatment. As acceptance within society of mental health issues improves, more patients are expected to seek help, increasing overall expansion in the bipolar therapeutics market. This mix sets the bipolar disorder market up to have a great future in the coming years. For instance, as per WHO data, more than 40 million patients have bipolar disorder across the globe, and according to the latest Global Burden of Disease (GBD) study, around 2.4% of the global population is affected by bipolar disorder.

Advancements in Diagnostic Tools Drive Market Growth

Advances in diagnostic tools are also a significant growth area in the bipolar disorder market as sophisticated mechanisms increase the precision of their identification and subsequent treatments. Recent developments include a relatively simple blood test, which can diagnose as much as 30% of cases of bipolar disorder-especially in conjunction with online psychiatric assessments. This advance clarifies differences between bipolar disorder and other closely related diagnoses, such as major depressive disorder, often over-diagnosed. With growing awareness and reduced stigma, more patients seek timely diagnoses, thus fueling the market demand. Technological advancement also helps better manage patients by including mood pattern monitoring applications in the patient's smartphone. Increased diagnosis leads to interventions at earlier stages, thus better interventions and, subsequently, more drugs and therapies for the disorder of bipolar. This trend is expected to continue with further research and tools. For instance, in April 2024, SYNLAB International GmbH marked World Bipolar Day 2024 by announcing the launch of a revolutionary test for diagnosing bipolar disorder in France. The myEDIT-B test is the first clinically validated test for differentiating between bipolar disorder and unipolar depression, using RNA editing changes in patients' blood.

Mood Stabilizers Segment to Dominate With Highest Market Share

Mood stabilizers are one of the most used medications for bipolar disorder. They are effective in the stabilization of mood swings and the prevention of both manic and depressive episodes, thus holding the major share in the bipolar disorder market. Among all the discovered mood stabilizers, lithium was the first in use to treat patients with mania. It had long been used in the treatment of mania. It was known for its efficacy in reducing the frequency as well as severity of manic episodes with protection against depression. Other drugs have also been effective, the best examples being valproate and lamotrigine, though these are most effective for certain types of bipolar. They stabilize the shifting patterns of mood as much as possible, helping a person stay balanced and permitting daily functioning to improve. Adding further strength to their position as the foundation in bipolar disorder treatment is their ability to improve quality of life and prevent recurrence. For instance, several mood stabilizer drugs approved by USFDA in recent times include Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Aripiprazole (Abilify), Lurasidone (Latuda), Asenapine (Saphris), Cariprazine (Vraylar), and Lumateperone (Caplyta).

Asia-Pacific Dominates the Bipolar Disorder Market

Asia-Pacific is anticipated to register a fast CAGR and, thus, exponential growth. Compared to the historical years, the diagnosis and recognition of mental health conditions are more prevalent in Asia-Pacific now, thereby increasing the demand for efficient treatment options significantly. In addition, with the effect of continuous urbanization and a change in lifestyle increasing stress factors, more people are now approaching health professionals for solutions to these mental health issues. Improved governmental initiatives and a boost in healthcare infrastructure are also increasing psychiatric services and medications. At the same time, the Asia-Pacific region is witnessing increasing investment from pharmaceutical companies that focus on the research and development of new therapies targeted at the peculiar needs of diverse populations. Mental health is slowly eroding its stigma, and more patients are encouraged to seek treatment. As such, these factors make the Asia-Pacific market for bipolar disorder treatment a rising area and an attractive investment opportunity for stakeholders in the healthcare industry. For instance, according to the National Mental Health Survey conducted in India, the prevalence of bipolar disorder in India is 0.5%, which comes out to be affecting more than 7 million people in India.

Future Market Scenario (2024-2031F)

The rise of digital therapeutics and online cognitive behavioral therapy (CBT) offers accessible, effective management tools for patients. These platforms can reduce depressive symptoms and improve overall well-being by providing real-time support and monitoring.

Devices that monitor sleep patterns and physical activity are proving effective in managing symptoms. Research indicates that regular tracking of these factors can stabilize mood, leading to more tailored treatment approaches.

Discoveries related to specific genes, like AKAP11, provide a deeper understanding of bipolar disorder's molecular mechanisms, paving the way for novel therapies that target these pathways.

Key Players Landscape and Outlook

The market for pharmaceuticals for bipolar disorder is being catered to by several players ranging from small startups to global pharmaceutical giants. Recent market activities include innovative product launches, acquisition deals, and regulatory approvals, which are anticipated to expand the market in the forecast period.

In March 2024, Bristol Myers Squibb (BMS) completed its acquisition of Karuna Therapeutics, broadening its neuroscience portfolio. This strategic move includes the integration of KarXT (xanomeline-trospium), an innovative antipsychotic with a unique mechanism of action, which is currently under review for treating schizophrenia. Notably, KarXT is also in trials for additional indications, including Bipolar I disorder, and agitation associated with Alzheimer's disease, highlighting its potential to address a range of mental health conditions. The acquisition is expected to bolster BMS's growth trajectory, aligning with its commitment to expanding treatment options in neuroscience.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Bipolar Disorder Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Generic
    • 4.2.1.2. Branded
  • 4.2.2. By Drug Class
    • 4.2.2.1. Mood Stabilizer
    • 4.2.2.2. Anticonvulsants
    • 4.2.2.3. Anti-Psychotic Drugs
    • 4.2.2.4. Anti-Depressant Drugs
    • 4.2.2.5. Anti-Anxiety Drugs
  • 4.2.3. By Disorder Type
    • 4.2.3.1. Bipolar I Disorder
    • 4.2.3.2. Bipolar II Disorder
    • 4.2.3.3. Cyclothymic Disorder
  • 4.2.4. By Route of Administration
    • 4.2.4.1. Oral
    • 4.2.4.2. Parenteral
  • 4.2.5. By Distribution Channel
    • 4.2.5.1. Hospital Pharmacies
    • 4.2.5.2. Retail Pharmacies
    • 4.2.5.3. Online Pharmacies
  • 4.2.6. By Region
    • 4.2.6.1. North America
    • 4.2.6.2. Europe
    • 4.2.6.3. Asia-Pacific
    • 4.2.6.4. South America
    • 4.2.6.5. Middle East and Africa
  • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Type
  • 4.3.2. By Drug Class
  • 4.3.3. By Disorder Type
  • 4.3.4. By Route of Administration
  • 4.3.5. By Distribution Channel
  • 4.3.6. By Region

5. North America Bipolar Disorder Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Type
    • 5.2.1.1. Generic
    • 5.2.1.2. Branded
  • 5.2.2. By Drug Class
    • 5.2.2.1. Mood Stabilizer
    • 5.2.2.2. Anticonvulsants
    • 5.2.2.3. Anti-Psychotic Drugs
    • 5.2.2.4. Anti-Depressant Drugs
    • 5.2.2.5. Anti-Anxiety Drugs
  • 5.2.3. By Disorder Type
    • 5.2.3.1. Bipolar I Disorder
    • 5.2.3.2. Bipolar II Disorder
    • 5.2.3.3. Cyclothymic Disorder
  • 5.2.4. By Route of Administration
    • 5.2.4.1. Oral
    • 5.2.4.2. Parenteral
  • 5.2.5. By Distribution Channel
    • 5.2.5.1. Hospital Pharmacies
    • 5.2.5.2. Retail Pharmacies
    • 5.2.5.3. Online Pharmacies
  • 5.2.6. By Country Share
    • 5.2.6.1. United States
    • 5.2.6.2. Canada
    • 5.2.6.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Bipolar Disorder Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Type
        • 5.3.1.2.1.1. Generic
        • 5.3.1.2.1.2. Branded
      • 5.3.1.2.2. By Drug Class
        • 5.3.1.2.2.1. Mood Stabilizer
        • 5.3.1.2.2.2. Anticonvulsants
        • 5.3.1.2.2.3. Anti-Psychotic Drugs
        • 5.3.1.2.2.4. Anti-Depressant Drugs
        • 5.3.1.2.2.5. Anti-Anxiety Drugs
      • 5.3.1.2.3. By Disorder Type
        • 5.3.1.2.3.1. Bipolar I Disorder
        • 5.3.1.2.3.2. Bipolar II Disorder
        • 5.3.1.2.3.3. Cyclothymic Disorder
      • 5.3.1.2.4. By Route of Administration
        • 5.3.1.2.4.1. Oral
        • 5.3.1.2.4.2. Parenteral
      • 5.3.1.2.5. By Distribution Channel
        • 5.3.1.2.5.1. Hospital Pharmacies
        • 5.3.1.2.5.2. Retail Pharmacies
        • 5.3.1.2.5.3. Online Pharmacies
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Bipolar Disorder Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Bipolar Disorder Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Bipolar Disorder Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Bipolar Disorder Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Clinical Trials
• 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. AbbVie Inc.
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. GlaxoSmithKline plc
  • 20.3.3. Eli Lilly and Company
  • 20.3.4. Janssen Pharmaceuticals, Inc.
  • 20.3.5. Astellas Pharma Inc.
  • 20.3.6. Bristol Myers Squibb Company
  • 20.3.7. Pfizer Inc.
  • 20.3.8. Novartis AG
  • 20.3.9. Otsuka Pharmaceutical Co., Ltd.
  • 20.3.10. AstraZeneca PLC

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer